

Division of Signal Transduction Therapy

Standard Operating Procedure

Preparation of active TTK [1 - 857]

Enzyme description:- TTK [1 – 857]

Clone number:- DU 8837

Source:- Recombinant

Expression system:- Baculovirus expression vector system

Tag:- N-terminal His(6) tag

Purification method:- Ni²⁺-NTA agarose

Expression level:- 1 mg/L

Calculated molecular mass:-

Monoisotopic 100,380.51 daltons

Average Mass 100,443.89 daltons

[cysteines reduced, methionines have not been oxidised]

Theoretical pI:- 8.10

Purity:- 75 %

Activation protocol:- Constitutively active

Enzyme storage buffer:-

50 mM Tris-HCl pH 7.5, 270 mM sucrose, 150 mM NaCl, 0.1 mM EGTA,
0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 0.2 mM PMSF, 1 mM Benzamidine.

Storage temperature:- -70 °C [Long term stability to be determined]

Assay:- Standard filter binding assay

Assay Buffer:-

50 mM Tris-HCl pH 7.5, 0.1mM EGTA, 0.1 % 2-mercaptoethanol, 10 mM MgAc

Substrate:-

RSRSRSRSRSRSR residues 204 – 218 of human ASF-1/SF-2

Final concentration: 300 μ M

Specific activity range:- To be determined

Division of Signal Transduction Therapy

Clone Data Sheet

TTK [1 - 857]

Protein TTK [1 – 857]

Clone Number DU 8837

Species Human

Accession number NM_003318

Tags N-terminal His(6)

Baculovirus expressed protein

MSYYHHHHHDYDIPTTENLYFQGAMGSMESDLSGRELTIDSIMNKVR
DIKNKFKNEDLTDELSLNKISADTTDNSGTVNQIMMANNPEDWLSLLL
KLEKNSVPLSDALLNKLIGRYSQAIEALPPDKYGQNESFARIQVRFAEL
KAIQEPDDARDYFQMARANCKKFAFVHISFAQFELSQGNVKKSKQLLQK
AVERGAVPLEMLEIALRNLNLQKKQLLSEEEKKNLSASTVLTAEFSFG
SLGHLQNRNNSCDSRGQTTKARFLYGENMPPQDAEIGYRNSLRQTNKTK
QSCPFGRPVFNLLNSPDCDVKTDDSVVPCFMKRQTSRSECRDLVVP GSK
PSGNDSCELRNLSVQNSHFKEPLVSDEKSSSELIITDSITLKNKTESSL
LAKLEETKEYQEPEVPESNQQWQSKRKSECINQNPAASSNHWQIPELA
RKVNTEQKHTTFEQPVFSVSKQSPPISTSKWFDPKSICKTPSSNTLDDY
MSCFRTPVVKNDFFPACQLSTPYGQPACFQQQQHQILATPLQNLQVLAS
SSANECISVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEA
DNQTLDSYRNEIAYLNKLQQHSCKIIRLYDYEITDQYIYMVMCEGNIDL
NSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDG
MLKLIDFGIANQMOPDTSVVKDSQVGTVNYPPEAIKDMSSSRENGKS
KSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEF
PDIPEKDLQDVLKCLKRPKQORISIPELLAHPYVQIQTHPVNQMAKGT
TEEMKYVLGQLVGLNSPNSILKAAKTLYEYSGGESHNSSSSSKTFEKKR
GKK

Native sequence Amino acids M1 – K857 (end) of human TTK.
Residue M29 of fusion protein is equivalent to M1 of the native
enzyme. The His(6) tag is located at residues 5 – 10.

Protease cleavage rTEV (ENLYFQG) residues 18 - 24

Cloning sites *Bam*H1 and *Not*I site of pFastBAC HTb

Division of Signal Transduction Therapy

Nucleotide sequence of insert

ggatccATGGAATCCGAGGATTTAAGTGGCAGAGAATTGACAATTGATT
CCATAATGAACAAAGTGAGAGACATTAAAAATAAGTTTAAAAATGAAGA
CCTTACTGATGAACCTAAGCTTGAATAAAATTTCTGCTGATACTACAGAT
AACTCGGGAAGTGTAAACCAAAATTATGATGATGGCAAACAACCCAGAGG
ACTGGTTGAGTTTGTGCTCAAACCTAGAGAAAAACAGTGTTCCGCTAAG
TGATGCTCTTTTAAATAAAATTGATTGGTCGTTACAGTCAAGCAATTGAA
GCGCTTCCCCCAGATAAATATGGCCAAAATGAGAGTTTTGCTAGAATTC
AAGTGAGATTTGCTGAATTAAAAGCTATTCAAGAGCCAGATGATGCACG
TGACTACTTTCAAATGGCCAGAGCAAACCTGCAAGAAATTTGCTTTTGT
CATATATCTTTTGCACAATTTGAACTGTCACAAGGTAATGTCAAAAAA
GTAAACAACCTTCTTCAAAAAGCTGTAGAACGTGGAGCAGTACCACTAGA
AATGCTGGAAATTGCCCTGCGGAATTTAAACCTCCAAAAAAGCAGCTG
CTTTCAGAGGAGGAAAAGAAGATTTATCAGCATCTACGGTATTAAGT
CCCAAGAATCATTTTCCGGTTCACCTGGGCATTTACAGAATAGGAACAA
CAGTTGTGATTCCAGAGGACAGACTACTAAAGCCAGGTTTTTATATGGA
GAGAACATGCCACCACAAGATGCAGAAATAGGTTACCGGAATTCATTGA
GACAACTAACAAAACCTAAACAGTCATGCCCATTTGGAAGAGTCCAGT
TAACCTTCTAAATAGCCCAGATTGTGATGTGAAGACAGATGATTCAGTT
GTACCTTGTTTTATGAAAAGACAAACCTCTAGATCAGAATGCCGAGATT
TGGTTGTGCCTGGATCTAAACCAAGTGGAATGATTCTGTGAATTAAG
AAATTTAAAGTCTGTTCAAAATAGTCATTTCAAGGAACCTCTGGTGTCA
GATGAAAAGAGTTCTGAACCTTATTATTACTGATTCAATAACCCTGAAGA
ATAAAACGGAATCAAGTCTTCTAGCTAAATTAGAAGAACTAAAGAGTA
TCAAGAACCAGAGGTTCCAGAGAGTAACCAGAAACAGTGGCAATCTAAG
AGAAAGTCAGAGTGTATTAACCAGAATCCTGCTGCATCTTCAAATCACT
GGCAGATTCCGGAGTTAGCCCGAAAAGTTAATACAGAGCAGAAACATAC
CACTTTTGAGCAACCTGTCTTTTCAGTTTCAAAACAGTCACCACCAATA
TCAACATCTAAATGGTTTGACCCAAAATCTATTTGTAAGACACCAAGCA
GCAATACCTTGGATGATTACATGAGCTGTTTTAGAACTCCAGTTGTAAA
GAATGACTTTCCACCTGCTTGTGTCAGTTGTCAACACCTTATGGCCAACCT
GCCTGTTTCCAGCAGCAACAGCATCAAATACTTGCCACTCCACTTCAAA
ATTTACAGGTTTTTAGCATCTTCTTCAGCAAATGAATGCATTTTCGGTTAA
AGGAAGAATTTATTCATTTTAAAGCAGATAGGAAGTGGAGGTTCAAGC
AAGGTATTTAGGTGTAAATGAAAAGAAACAGATATATGCTATAAAAT
ATGTGAACTTAGAAGAAGCAGATAACCAAACCTTGTATAGTTACCGGAA
CGAAATAGCTTATTTGAATAAACTACAACAACACAGTGATAAGATCATC
CGACTTTATGATTATGAAATCACGGACCAGTACATCTACATGGTAATGG
AGTGTGGAAATATTGATCTTAATAGTTGGCTTAAAAAGAAAAATCCAT
TGATCCATGGGAACGCAAGAGTTACTGGAAAAATATGTTAGAGGCAGTT
CACACAATCCATCAACATGGCATTGTTACAGTGATCTTAAACCAGCTA
ACTTTCTGATAGTTGATGGAATGCTAAAGCTAATTGATTTTGGGATTGC
AAACCAAATGCAACCAGATACAACAAGTGTGTAAAGATTCTCAGGTT
GGCACAGTTAATTATATGCCACCAGAAGCAATCAAAGATATGTCTTCCT
CCAGAGAGAATGGGAAATCTAAGTCAAAGATAAGCCCCAAAAGTGATGT
TTGGTCCTTAGGATGTATTTTGTACTATATGACTTACGGGAAAACACCA
TTTCAGCAGATAATTAATCAGATTTCTAAATTACATGCCATAATTGATC
CTAATCATGAAATTGAATTTCCCGATATTCCAGAGAAAGATCTTCAAGA

Division of Signal Transduction Therapy

TGTGTTAAAGTGTGTTTAAAAAGGGACCCAAAACAGAGGATATCCATT
CCTGAGCTCCTGGCTCATCCCTATGTTCAAATTCAACTCATCCAGTTA
ACCAAATGGCCAAGGGAACCACTGAAGAAATGAAATATGTTCTGGGCCA
ACTTGTGCTCTGAATTCTCCTAACTCCATTTTGAAAGCTGCTAAACT
TTATATGAACACTATAGTGGTGGTGAAAGTCATAATTCTTCATCCTCCA
AGACTTTTGAAAAAAAAAAGGGGAAAAAAAtgagcggccgc